Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Consensus Price Target of $9.17 According to Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.17.

Several equities research analysts have recently weighed in on AQST shares. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Monday, August 24th. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th.

Insider Buying and Selling

In other news, CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $4.82, for a total value of $120,500.00. Following the completion of the sale, the chief executive officer directly owned 652,317 shares of the company’s stock, valued at approximately $3,144,167.94. This trade represents a 3.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the sale, the insider owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.81% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AQST. Blue Owl Capital Holdings LP bought a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $3,923,000. Latash Investments LLC acquired a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $1,011,000. Wasatch Advisors LP raised its position in Aquestive Therapeutics by 57.8% during the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock worth $5,765,000 after acquiring an additional 507,527 shares in the last quarter. BlackRock Inc. bought a new position in Aquestive Therapeutics during the second quarter worth about $33,569,000. Finally, Walleye Capital LLC bought a new stake in Aquestive Therapeutics in the second quarter valued at approximately $1,175,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $4.55 on Friday. The firm has a market capitalization of $571.07 million, a price-to-earnings ratio of -7.00 and a beta of 1.49. Aquestive Therapeutics has a 52-week low of $2.93 and a 52-week high of $7.55. The company’s fifty day moving average is $4.59 and its two-hundred day moving average is $4.32.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. As a group, sell-side analysts expect that Aquestive Therapeutics will post -0.5 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.

Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.